Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders

Phase 2 Recruiting 14 enrolled Mayo Clinic

NaSingle-groupOpen-labelTreatment

Summary

The researchers are testing a medication named ravulizumab for the treatment of severe preeclampsia and Hemolysis, Elevated Liver enzymes, Low Platelets (HELLP) syndrome.

Timeline

Start: 2026-09-01
Primary completion: 2028-12-31
Completion: 2028-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ravulizumab	Monoclonal antibody	100 mg/ml	Intravenous

Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders

Summary

Timeline

Drugs

Indications